Skip to Content

Join the 'Lumigan' group to help and get support from people like you.

Lumigan News

Generic Eye Drops for Seniors Could Save Millions of Dollars a Year

Posted 28 Jul 2017 by

FRIDAY, July 28, 2017 – Prescribing generic drugs for seniors' eye problems could save the U.S. government hundreds of millions of dollars a year, a new study suggests. Conditions like glaucoma and dry eye that require daily eye drops are common in old age. University of Michigan researchers report that eye doctors caring for seniors prescribe brand-name medications in more than three-quarters of cases, compared to one-third of cases among nearly all other specialties. "Lawmakers are currently looking for ways to reduce federal spending for health care, and policies that favor generics over brand medications or allow Medicare to negotiate drug prices may lead to cost savings," said study senior author Lindsey De Lott, of the university's Kellogg Eye Center. "Using a brand medication for a single patient may not seem like a big deal, but ultimately, these higher costs are paid by all of ... Read more

Related support groups: Eye Conditions, Glaucoma, Eye Dryness/Redness, Cataract, Glaucoma (Open Angle), Lumigan, Latanoprost, Travatan, Xalatan, Combigan, Travatan Z, Alphagan, Systane, Refresh, Dry Eye Disease, Cosopt, Azopt, Brimonidine, Dorzolamide, Zioptan

Lupin Receives FDA Approval for Generic Lumigan Ophthalmic Solution 0.03%

Posted 23 Feb 2015 by

Mumbai, India and Baltimore, Maryland – February 23, 2015: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Bimatoprost Ophthalmic Solution, 0.03% from the United States Food and Drugs Administration (FDA) to market a generic version of Allergan Inc.'s Lumigan Ophthalmic Solution, 0.03%. Lupin Pharmaceuticals Inc. (LPI), the company's U.S. subsidiary would commence marketing the product shortly. Lupin's Bimatoprost Ophthalmic Solution, 0.03% is the AT rated generic equivalent of Lumigan Ophthalmic Solution, 0.03% and is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Lupin's Bimatoprost Ophthalmic Solution, 0.03% filing was made from its Indore facility which was audited in January, 2015. Two Lupin facilities, the Lupin Bioresearch Center, Pune (LBC) and its ... Read more

Related support groups: Glaucoma, Glaucoma (Open Angle), Lumigan, Glaucoma/Intraocular Hypertension, Bimatoprost

Illegal Online Meds Targeted in Worldwide Crackdown, FDA Says

Posted 25 May 2014 by

THURSDAY, May 22, 2014 – Illegal online pharmacies that sell unapproved and potentially dangerous prescription drugs to Americans were targeted this week in a worldwide operation, the U.S. Food and Drug Administration said Thursday. More than 19,600 packages containing medicines supposedly from Australia, Canada, New Zealand and Great Britain were seized in the action, which involved authorities from 111 countries, the FDA said in a news release. The packages actually contained unapproved or suspected fake drugs from countries such as China, India, Laos, Malaysia, Mexico, Singapore and Taiwan, as well as Australia, New Zealand and Great Britain, the agency reported. In the United States, officials inspected shipments at international mail facilities in Los Angeles, Chicago and New York City and seized or detained 583 packages. Many of the packages contained illegal prescription ... Read more

Related support groups: Tramadol, Viagra, Cialis, Ultram, Sildenafil, Tadalafil, Lumigan, Dromadol SR, Revatio, Adcirca, Ultram ER, Tramal, Ryzolt, GenRx Tramadol, Zydol, Ultram ODT, Tramahexal, ConZip, Tramahexal SR, Bimatoprost

Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds

Posted 24 May 2013 by

FRIDAY, May 24 – Drugs commonly used to treat glaucoma may cause droopy eyelids and other side effects that can interfere with vision, according to a new study. The drugs, known as prostaglandin analogues (PGAs), which are used to reduce eye pressure, have already been shown to cause blurred vision, dryness and changes in eye color, the researchers said, suggesting that the new findings could lead to labeling changes for PGAs. Doctors should be conservative when prescribing these drugs, the researchers added, particularly as a preventive measure for patients at risk for glaucoma. "The loss of periorbital fat was previously described by us in a small series of unilateral PGA users," senior study author Dr. Louis Pasquale, director of the glaucoma service at the Massachusetts Eye and Ear Infirmary, said in an infirmary news release. "Those observations did ultimately lead to a change in ... Read more

Related support groups: Glaucoma, Lumigan, Latanoprost, Travatan, Xalatan, Travatan Z, Travoprost, Bimatoprost

Allergan, Inc. Receives FDA Approval for Lumigan 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients

Posted 5 Sep 2010 by

IRVINE, Calif.--(BUSINESS WIRE)--Aug 31, 2010 - Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved Lumigan (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Lumigan 0.01% is an optimized reformulation of Lumigan (bimatoprost ophthalmic solution) 0.03%. "The approval of Lumigan 0.01% provides doctors with an efficacious, safe and well-tolerated IOP-lowering medication for glaucoma patients who are either starting treatment or are changing their medication regimen," said Scott Whitcup, M.D., Allergan's Executive Vice President, Research and Development, Chief Scientific Officer. "Lumigan 0.01% exemplifies Allergan's commitment to developing medications for glaucoma patients that maximize efficacy while ... Read more

Related support groups: Lumigan, Bimatoprost

FDA Medwatch Alert: Age Intervention Eyelash

Posted 19 Nov 2007 by

[Posted 11/19/2007] FDA informed healthcare professionals and consumers of the seizure of 12,682 applicator tubes of Age Intervention Eyelash, sold and distributed by Jan Marini Skin Research, Inc. of San Jose, California. The product was seized because it may lead to decreased vision in some users. The eyelash product is an unapproved and misbranded drug because it is promoted to increase eyelash growth. Before a new drug product may legally be marketed, it must be shown to be safe and effective, and approved by FDA. FDA considers the product to be an adulterated cosmetic because it contains bimatoprost, an active ingredient in an FDA-approved drug to treat elevated intraocular pressure (elevated pressure inside the eye). Use of the prescription drug in addition to the eyelash product containing the drug, may increase the risk of optic nerve damage because the extra dose of bimatoprost ... Read more

Related support groups: Lumigan

Ask a Question

Further Information

Related Condition Support Groups

Glaucoma (Open Angle), Intraocular Hypertension

Lumigan Patient Information at